AdaptHealth 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third quarter net revenue was $745.6 million, up 10.9% versus the prior year quarter and 12.8% on an organic basis; revenue was $15.6 million above the midpoint of guidance.
- Adjusted EBITDA was $141.9 million, compared with $146.1 million in the prior year quarter, and was $11.2 million above the guidance midpoint; free cash flow was $51.1 million.
- The largest capitated contract contributed 10.7 percentage points of quarterly organic growth, while base business organic growth contributed 2.1 percentage points.
- The largest capitated contract delivered an approximately 10% margin in the quarter, up from a negative margin of 4% in the second quarter, and was tracking at an approximately 14% run rate as the quarter ended.
- Net loss attributed to AdaptHealth was $168.2 million, primarily reflecting a $184.8 million non-cash, pre-tax goodwill impairment charge; AdaptHealth also recognized a $12 million pre-tax gain from contributing its e-commerce business to a joint venture.
- Net debt was $1.85 billion, unrestricted cash was $80.7 million, and the consolidated total leverage ratio was 3.05 times; year-to-date free cash flow was $2.6 million.
- Capital expenditures were $105.5 million, or 14.2% of consolidated net revenue, as elevated spending to equip the capitated contract subsided.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone, and welcome to today's AdaptHealth Third Quarter 2026 Earnings Release. Today's speakers will be Suzanne Foster, Chief Executive Officer of AdaptHealth, and Harriss Currie, Chief Financial Officer of AdaptHealth. Before we begin, I'd like to remind everyone that statements included in this conference call and in the press release issued today may constitute forward-looking statements within the meaning of Private Securities Litigation Reform Act. These statements include, but are not limited to, comments regarding financial results for 2026 and beyond. Actual results could differ materially from those projected in forward-looking statements because of the number of risk factors and uncertainties, which are discussed at length in the company's annual and quarterly SEC filings. AdaptHealth Corp. has no obligation to update the information provided on this call to reflect such subsequent events.
Additionally, on this morning's call, the company will reference certain financial measures such as EBITDA, adjusted EBITDA, adjusted EBITDA margin, and free cash flow, all of which are non-GAAP financial measures. You can find more information about these non-GAAP measures in the presentation materials accompanying today's call, which are posted on the company's website. This morning's call is being recorded, and a replay of the call will be available later today. I am now pleased to introduce the Chief Executive Officer of AdaptHealth, Suzanne Foster.
Good morning, everyone, and thank you for joining us today. First order of business is to welcome Harriss Currie, who joined AdaptHealth as our Chief Financial Officer in September. Harriss will take you through our financial results and outlook after my remarks. The third quarter was a step in the right direction. We delivered strong organic growth, exceeded our guidance for revenue and adjusted EBITDA, and met our free cash flow target, driven in large part by meaningful improvement in the performance of our largest capitated contract and by a base business that continues to produce consistent performance.
This morning, I'll overview our third quarter results, update you on the two issues that weighed on our outlook last quarter, the capitated contract and an unexpected price increase from a large manufacturer, and then give you a brief update on the pending sale of our Diabetes Health business and on Medline's field action announcement about its beds. Starting with our results, as a reminder, all figures are provided on a continuing operations basis, including prior period comparisons, except for capital expenditures and free cash flow, which will include Diabetes Health until the sale closes. Third quarter net revenue was $745.6 million, up 10.9% versus the prior year quarter, and up 12.8% on an organic basis. Adjusted EBITDA was $141.9 million, $11.2 million above the midpoint of our implied third quarter guidance range, and free cash flow was $51.1 million, slightly ahead of our guidance.
Harriss will take you through the details in a moment. Behind these results, the biggest driver was the improvement in our largest capitated contract, and specifically the West Coast operations associated with that contract. We have been working to stabilize the operation and align costs to serve with our original assumptions, and that work is now beginning to pay off. The contract made a positive contribution to adjusted EBITDA in the quarter, a swing from a loss in the second quarter, and better than break-even we assumed for the second half when we reset guidance in August. Two dynamics drove the improvement. First, utilization, while still well above our original expectations, has come down from the peak of the early months, particularly in sleep resupply as the backlog of pent-up demand cleared.
Capital spending also declined sequentially as we completed the one-time purchase of vehicles and initial buildup of patient equipment. Second, we tightened the labor model. Headcount dedicated to the contract, including temporary staff, couriers, and contract workers, is down more than 12% since the end of the second quarter. As a result, we have lowered our costs even with utilization still elevated and while exceeding our service level requirements and commitments. We are certainly encouraged by the trajectory of the contract's profitability. September's run rate margin contribution was stronger than July's, and the progress we are making gives us confidence we will achieve a 20% margin on the contract by the fourth quarter of next year. We also continue to work with our partner on the economics of the contract and are making progress with those discussions.
The data supports our premise that utilization was running above our expectations on which the contract was priced. We have been provided assurances that pricing adjustments are coming. While we do not yet know the final impact of our negotiations, we are holding on any unilateral movements under the agreement while we continue to negotiate in good faith as partners. Although we expect the agreement to be modified this quarter, we have not assumed a change to the terms in the revised outlook we are providing today. As I mentioned last quarter, there is also an opportunity to use our newly established footprint to serve patients beyond the capitated membership.
The moratorium on enrollment of new suppliers in Medicare that directly affected us was lifted in August, and we are submitting our applications for new PTANs, which are the Medicare billing numbers that allow us to operate more broadly in California. This will ultimately allow us to compete for fee-for-service business in that market. As a reminder, that opportunity is not included in our contract margin target of at least 20%. Next, the manufacturer price increase. As a reminder, we were notified on June 30th that a manufacturer was terminating our contract and imposing an immediate price increase, which we estimated would reduce second-half adjusted EBITDA by approximately $30 million. Since then, we have reached an agreement on a rebate structure that allows us to recover a portion of the lost economics.
We realized the benefit of $8 million in the third quarter as a result of purchases made during the quarter. We will carefully weigh further opportunities to capture discounts within this arrangement, as well as across all of our vendors, against our business needs and cash flow management. We have an arrangement in place for the 2026 contract year, and we are now back to our normal annual negotiation cycle with the manufacturer. Turning to the portfolio, a brief update. The HSR waiting period has expired for the sale of our Diabetes Health business to Cardinal Health. Transition activities are progressing as planned, and we expect to close early in 2027, subject to customary closing conditions. As a reminder, following the move of Diabetes Health to discontinued operations, our continuing operations results carry about $60 million of corporate overhead that was previously allocated to that business.
Of the $60 million, about half has been specifically associated with Diabetes Health activity and expected to dissipate beginning on day one through 12 months after the close of the transaction. The remaining $30 million of overhead is true stranded cost that we expect to absorb through growth and expense discipline over the next few years. With the portfolio work now largely behind us, we are a focused Sleep Health, Respiratory Health, and Wellness at Home business, where growth and margins are more attractive. The clinical value we add is greater, and our resupply operations keeps us in continuing relationship with patients. Now, a word on Medline. You may have seen that Medline has announced it is removing its brand of beds from the market, following earlier safety notices on certain home care beds. We are following Medline's instructions.
We are communicating directly with affected patients and caregivers, and we are working to repair or replace affected beds on a reasonable timeline. Medline beds are a meaningful part of our bed suite, and the replacement will take place over multiple quarters. We expect Medline to stand behind its products, and we are working with them to address the full cost of replacement. We will update you as that work progresses. We saw continued evidence this quarter that the underlying business is improving and stable. Our enterprise sales strategy is gaining traction as we sign preferred provider agreements with four large health systems, and we broadened our capitated portfolio with two smaller agreements with regional health plans, one new and one expanded. Our strategy is focused on being the easiest and most reliable supplier for patients and physicians to work with.
We continue to gain traction with digital tools that enhance the entire patient journey and connect the patient experience. myAPP now has more than 615,000 registered users, up about 20% from last quarter and nearly double where we ended last year. The AI-powered mask-fitting tool we introduced last quarter has now completed more than 12,600 scans, with roughly 94% of those resulting in a completed order. Importantly, leveraging this technology also helps us control our labor and OpEx costs. Let me close with where we go from here. The business is stabilizing after the largest patient transition in the history of the industry, and the third quarter demonstrates that the actions we took in the first half are gaining traction. With the pending sale of our Diabetes Health business, we are on the verge of completing our multi-year effort to focus our portfolio.
Our priorities are to augment the returns on our largest capitated contract and to return to delivering predictable, consistent results. Our base business continues to grow organically, and I'm grateful to our teams who have put patients first through a demanding year and are heading into next year with momentum. With that, let me turn it over to our new CFO, Harriss Currie, to review the financials.
Thank you, Suzanne, and good morning, everyone. I'm certainly pleased to be here, and I look forward to meeting many of you in the near future. I'll cover our third quarter results, the balance sheet, cash flow, and our updated outlook. As noted, all figures are provided on a continuing operations basis, including prior period comparisons, except for CapEx and free cash flow, which includes Diabetes Health until the sale closes. Third quarter net revenue of $745.6 million increased 10.9% versus the prior year quarter, with organic growth of 12.8%. We displayed year-to-date growth in revenue over the prior year of 9.7%. Our third quarter revenue was $15.6 million above the midpoint of our guidance, driven primarily by growth in referrals and resupply in our Sleep Health segment, and a slower-than-anticipated reduction in revenue related to the decision to cease actively marketing certain products within our PCS business.
On a reported basis, Sleep Health net revenue was $393.9 million, up 11%. Respiratory Health net revenue was $190.8 million, up 7.8%. Wellness at Home net revenue was $161 million, up 14.5%. Total capitated revenue was $110.3 million, about 15% of our continuing operations net revenue, and more than three times that of the prior year. Our largest capitated contract contributed 10.7 percentage points of the 12.8% organic growth in the quarter. Base business organic growth contributed the remaining 2.1 percentage points of the 12.8% organic growth. Adjusted EBITDA was $141.9 million versus $146.1 million in the prior year quarter, a margin of 19% versus 21.7% a year ago. On a year-to-date basis, adjusted EBITDA declined by 4.2%. The year-over-year and year-to-date declines reflect the ramp of our largest capitated contract, partially offset by labor and OpEx discipline.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
